EP2882846A1 - Procédés et compositions pour la production rapide de cellules épithéliales pigmentées de la rétine à partir de cellules multipotentes - Google Patents

Procédés et compositions pour la production rapide de cellules épithéliales pigmentées de la rétine à partir de cellules multipotentes

Info

Publication number
EP2882846A1
EP2882846A1 EP13799830.8A EP13799830A EP2882846A1 EP 2882846 A1 EP2882846 A1 EP 2882846A1 EP 13799830 A EP13799830 A EP 13799830A EP 2882846 A1 EP2882846 A1 EP 2882846A1
Authority
EP
European Patent Office
Prior art keywords
medium
cells
culture medium
concentration
rpe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13799830.8A
Other languages
German (de)
English (en)
Other versions
EP2882846A4 (fr
EP2882846B1 (fr
Inventor
Dennis Clegg
David BUCHHOLZ
Roxanne CROZE
Britney PENNINGTON
Peter Coffey
Lyndsay LEACH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP2882846A1 publication Critical patent/EP2882846A1/fr
Publication of EP2882846A4 publication Critical patent/EP2882846A4/fr
Application granted granted Critical
Publication of EP2882846B1 publication Critical patent/EP2882846B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/35—Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Definitions

  • the invention relates to the field of cell culture, specifically the culturing of retinal pigmented epithelium (RPE) cells.
  • RPE retinal pigmented epithelium
  • the invention encompasses methods and compositions for the rapid and efficient production of RPE cells from pluripotent cells.
  • the invention further includes methods and compositions for the efficient expansion, maintenance, and culture of differentiated RPE cells from native and pluripotent cell sources.
  • the retinal pigmented epithelium is a layer of cells in the eye.
  • the RPE is overlaid by the sensory retina cells which perceive light and transmit visual information to the optic nerve.
  • Underlying the RPE is the choroid tissue, a vascularized region which supplies the overlying cells of the eye with water, nutrients and other compounds.
  • the RPE plays many critical roles in maintaining vision including isolating the tissues of the eye from the general circulatory system, maintaining the proper ionic environment, processing discarded outer photoreceptor elements from the photoreceptor cells of the neural retina, and protecting the retina from excess light.
  • RPE cells form a flat mosaic of hexagonal cells tightly bound at their junctions.
  • RPE cells exhibit abnormalities and dysfunction that affect vision.
  • AMD age-related macular degeneration
  • AMD is a leading cause of vision loss in persons 60 years of age and older. It is estimated that in the United States 30% of people over age 75 suffer from some form of AMD.
  • deposits of cellular debris (drusen) form between the RPE and the underlying nourishing choroid, leading to death and dysfunction of the RPE cells.
  • Choroidal neovascularization is an AMD subtype characterized by abnormal blood vessel proliferation of the choroidal tissue and the resultant loss of vision resulting from damage to the overlying retinal cells.
  • Geographic atrophy is another form of AMD characterized by atrophy of the retinal pigmented epithelial cells and the resultant death of the overlying retinal cells.
  • RPE cells derived from stem cells and induced pluripotent cells present such a potential source of abundant RPE tissues for transplant.
  • RPE cells derived from both human embryonic and induced pluripotent stem cells have been created and transplanted in rats and were shown to be functional (Carr et al., Protective Effects of Human iPS-Derived Retinal Pigment Epithelium Cell Transplantation in the Retinal Dystrophic Rat, PloS One 4(12):e8152 (2009)).
  • RPE cells from human embryonic stem cells are currently in clinical trials for the treatment of both AMD and Stargardt's macular dystrophy.
  • novel methods and compositions for producing high-quality RPE cells with very high yields (>80%). Additionally, the novel protocol disclosed herein is extremely fast, and usable quantities of cells may be produced in as little as two weeks. Also disclosed herein are methods and compositions for the efficient maturation, maintenance, and expansion of differentiated RPE cells.
  • the inventions described herein encompass the use of novel media formulations, encompassing a range of constituents and which may be applied in a specific sequence and with specific timing for the rapid differentiation of RPE cells from pluripotent cells. Additionally, the use of novel media compositions, and media
  • the invention comprises novel media formulations for the differentiation of RPE cells from pluripotent cells.
  • the invention comprises the supplementation of known media compositions with compositions that aid in the rapid and efficient differentiation of RPE cells from pluripotent cells.
  • the invention comprises methods of culturing pluripotent and differentiating cells in various media compositions for the rapid differentiation and maturation of such cultured cells into functional RPE cells.
  • the invention comprises kits which are made up of multiple media formulations, or media multiple supplements which may be added to a basal medium to create one of the media of the invention.
  • the invention comprises the use of ROCK inhibitors in culture media during various phases of the differentiation, maintenance, and expansion of RPE cell cultures.
  • RPE from Pluripotent Cells The invention provides novel methods of producing RPE cells from pluripotent cells utilizing a variety of media, the media being used in a sequence and timing which promotes very rapid differentiation of RPE cells.
  • Some of the media constituents utilized in the media of the invention are known in the differentiation of RPE cells.
  • nicotinamide is known to promote differentiation of RPE from pluripotent cells (as described in Idelson M, Alper R, Obolensky A et al. Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. Cell Stem Cell 2009;5:396 - 408).
  • VIP has previously been used in the production of RPE cells (Koh SM.
  • VIP enhances the differentiation of retinal pigment epithelium in culture: From cAMP and pp60(c-src) to melanogenesis and development of fluid transport capacity. Prog Retin Eye Res 2000; 19:669 - 688).
  • the combinations of media constituents disclosed herein, and the timing of their application results in the production of RPE with unprecedented speed and efficiency. Drawing upon knowledge from developmental biology, retinal progenitor development, and other stem cell studies, the timing of factor addition has been optimized to generate high-quality RPE within 14 days, with high yields.
  • RPE cells refers to native pigmented retinal epithelial cells as well as pigmented retinal epithelial phenotype cells derived from pluripotent cell sources. Such cultured cells have a genetic expression profile similar to that of native RPE cells and assume the polygonal, planar sheet morphology of native RPE cells when grown to confluence on a planar substrate.
  • pluripotent cells refers to cells that can self-renew and proliferate while remaining in an undifferentiated state and that can, under the proper conditions, be induced to differentiate into specialized cell types, including RPE cells.
  • pluripotent cells encompass embryonic stem cells and other types of stem cells, including fetal, amnionic, or somatic stem cells.
  • Exemplary human stem cell lines include the H9 human embryonic stem cell line. Additional exemplary stem cell lines include those made available through the National Institutes of Health Human Embryonic Stem Cell Registry and the Howard Hughes Medical Institute HUES collection (as described in Cowan, C.A. et. al, Derivation of Embryonic Stem-cell Lines from Human Blastocysts. New England Journal of Medicine. 350; 13. (2004)).
  • pluripotent stem cells also encompasses induced pluripotent stem cells, a type of pluripotent stem cell which has been derived from a non-pluripotent cell, such as a somatic cell that has been
  • iPS cells can be created by inducing the expression of certain regulatory genes or by the exogenous application of certain proteins.
  • Methods for the induction of iPS cells are known in the art and include, for example, the methods described in Zhou et al., Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells, Stem Cells 27 (1 1): 2667-74 (2009), Huangfu et al, Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds, Nature Biotechnology 26 (7): 795 (2008); Woltjen et al., piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells, Nature 458 (7239): 766-770 (2009); Zhou et al., Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins, Cell Stem Cell 8:381-384
  • the invention encompasses the use of pluripotent cells from any species, including human, murine, porcine, canine, feline, rattus, and other mammal species. Cells derived through the use of the invention may be applied in any research or therapeutic use, including medical and veterinary uses.
  • Pluripotent cells can be cultured and differentiated to RPE using various culture methods and conditions known in the art.
  • Pluripotent cells may be grown in any type of suitable vessel including vessels made from glass, polystyrene, and polycarbonate.
  • the invention encompasses the use of any cell culture system, including 2-dimensional culture, three-dimensional culture, and liquid suspension culture techniques. Two-dimensional culture techniques are preferred for the ease of cell observation and passaging. Vessels of any size may be used, such as T-75 flasks (75 cm 2 surface area/flask), 96-well plates (0.32 cm 2 surface area/well), 24-well plates (1.9 cm 2 surface area/well), or six well plates (9.5 cm 2 surface area/well), for example BD FalconTM polystyrene plates.
  • Cell cultures should be maintained at or near 37°C. Adequate medium to avoid limiting growth should be added to each vessel, and medium should be changed at regular intervals to avoid depletion of nutrients and accumulation of waste substances. For example, using standard six-well plates (well diameter of 9.5 cm 2 ), about 2 ml of medium should be used per well.
  • the cell culture methods of the invention are carried out using a cell culture substrate.
  • the invention encompasses the use of any substrate which supports the growth of pluripotent cells, as well as the growth of differentiating cells, RPE progenitors, and RPE cells.
  • Exemplary substrates include commonly-used substrates such as Matrigel, mouse embryonic fibroblast feed cell layers, human embryonic fibroblasts, human fallopian tube epithelium, or human foreskin fibroblasts feeder layers, as known in the art.
  • Xeno-free substrates for example, commercially available substrates such as
  • SynthemaxTM (Corning Life Sciences), CELLstartTM (Invitrogen), GELstartTM (Invitrogen), and StemAdhereTM (Primorigen) may be used.
  • human vitronectin purified from human plasma or produced by recombinant expression, may serve as a xeno-free substrate for pluripotent cell growth, for example as described in Braam et al., Recombinant Vitronectin Is a Functionally Defined Substrate That Supports Human Embryonic Stem Cell Self-Renewal via 3 ⁇ 4 ⁇ 5 Integrin, Stem Cells 26:2257-2265 (2008).
  • Laminin 51 1 Laminin 51 1
  • Laminin 521 Laminin 521
  • poly-D-lysine may act as a substrate, for example as described in Harb et al., The Rho-Rock-Myosin Signaling Axis Determines Cell-Cell Integrity of Self- Renewing Pluripotent Stem Cells. PLoS ONE 3(8): e3001 (2008).
  • Molecular characterization For monitoring the stage of RPE differentiation, and for subsequent validation of RPE phenotype, the expression of various molecular markers may be assessed. Genetic markers can be confirmed by various methods known in the art. For example, expression of molecular markers may be quantified by quantifying marker gene mRNA, for example, by the use of qPCR methods as known in the art. Alternatively, expression of molecular markers may be assessed by quantification of marker gene translation products, for example by immunoassay, for example, immunocytochemistry and immunoblot assays.
  • Basal Media Culturing, including maintenance of pluripotent cells, differentiation of pluripotent cells into RPE, and expansion and maintenance of RPE cultures, is carried out in various media, as described herein.
  • the growth media of the invention are made by adding novel combinations of additives to a basal medium.
  • basal medium refers to a cell growth or cell culture medium in which pluripotent cells and their differ entiating/differentiated derivatives are cultured.
  • Basal medium refers to any solution of salts, sugars, amino acids and growth factors which supports the growth and maintenance of pluripotent cells and their differentiated derivatives, including pluripotent cell-derived RPE cells and their progenitors.
  • Exemplary basal media include those known in the art, for example Dulbecco's Modified Eagle Medium mammalian cell culture medium (DMEM) (Life Technologies). Another exemplary medium is Ham's F12 medium. Another exemplary medium is a 1 : 1 mixture of DMEM and F12. Another exemplary basal medium is Iscove's Modified Dulbecco's Medium (IMDM, from Life Technologies). Iscove's Modified Dulbecco's Medium (IMDM) (as described in Iscove, N.N., Guilbert, L.J. and Weyman, C. (1980).
  • IMDM Iscove's Modified Dulbecco's Medium
  • Exemplary commercially available xeno-free media include X-Vivo 10TM (Lonza Biosciences), X-Vivo 15TM (Lonza Biosciences), mTeSR2TM (Stem Cell Technologies), NutriStemTM (StemGent) and HEScGROTM (Millipore).
  • Lonza X-Vivo 10 supplemented with 5-40% Xeno-Free Knockout Serum Replacement (XF-KOSRTM, Invitrogen) or a similar xeno-free serum replacement may also be used.
  • xeno-free culture media include that described in Rajala et al., A Defined and Xeno-Free Culture Method Enabling the Establishment of Clinical- Grade Human Embryonic, Induced Pluripotent and Adipose Stem Cells, PloS ONE 5 :e 10246 (2010), the medium described in Swistowski et al., Xeno-Free Defined Conditions for Culture of Human Embryonic Stem Cells, Neural Stem Cells and Dopaminergic Neurons Derived from Them, PLoS ONE 4: e6233 (2009), and the medium described in Amit et al., Feeder layer- and serum- free culture of human embryonic stem cells, Biology of Reproduction 70:837 (2004). Additionally, the media described in Thompson et al., Embryonic Stem Cell Lines Derived from Human Blastocysts, Science 282: 1 145 (1998) or described at
  • Another exemplary basal medium is NeurobasalTM medium from Life Technologies.
  • Other exemplary basal media include Minimum Essential Medium Eagle (MEM), Roswell Park Memorial Institute Medium 1640 (RPMI- 1640, and MCDB medium.
  • Basal media may be supplemented with serum, for example fetal bovine serum.
  • serum replacements may be used, for example, Knockout Serum Replacement (Life Technologies).
  • Another exemplary serum substitute is B27 (Life Technologies).
  • Another exemplary serum replacement is N2 supplement, which may be used at about 1 % volume. Serum and serum replacements in general may be used at 1 -20%, by volume.
  • Basal media may also include additional supplements known in the art to improve the viability of cells and the efficiency of cell cultures.
  • L-glutamine or substitutes thereof for example GLUTAMAX- 1TM Supplement (Life Technologies) may be used to prevent ammonia buildup in cultures, for example at about 1-5 mM.
  • MEM-E NEAA Minimum Essential Medium Eagle with non-essential amino acids
  • B- mercaptoethanol may be used to preserve proteins in the medium, for example in
  • concentrations of about 0.05-0.5 mM. (025)
  • a 1 : 1 mixture of DMEM and F 12 supplemented with 1% N2 supplement, 2% B27, 2 mM GlutaMAX-I, 0.1 mM MEM NEAA. is used as a basal medium.
  • One additive used to formulate the novel media of the invention is noggin, a protein inhibitor of bone morphogenetic protein (BMP) and TGF-Beta signaling.
  • Recombinant noggin may be acquired from numerous commercial suppliers. Human derived recombinant noggin is preferred for the culture and differentiation of human pluripotent cells, although noggin derived from other mammalian species may be used as well.
  • Noggin mimics may be substituted for noggin in the media.
  • Noggin mimics encompass any compound which recapitulates the effects of noggin in the differentiation and maturation of RPE cells from pluripotent cells.
  • Noggin mimics include modified forms of noggin, peptides encompassing the noggin binding domains, and noggin analogs comprising substituted amino acids.
  • Exemplary noggin mimics include BMP inhibitors, i.e. any small molecule, peptide, or protein capable of inhibiting BMP pathway signaling.
  • Exemplary BMP inhibitors include the small molecules LDN-193189 (Stemgent) and Dorsomorphin (StemRD). Proteins that inhibit BMP signaling include chordin and cerberus (R&D Systems).
  • IGF1 insulin-like growth factor
  • Somatomedin C is a protein similar to insulin in its molecular structure.
  • Recombinant IGF1 may be acquired from numerous commercial suppliers. Human derived recombinant IGF1 is preferred for the culture and differentiation of human pluripotent cells, although IGF1 derived from other mammalian species may be used as well.
  • IGFl mimics may be substituted for IGFl in the media. IGFl mimics encompass any compound which recapitulates the effects of IGFl in the differentiation and maturation of RPE cells from pluripotent cells.
  • IGFl mimics include modified forms of IGFl, peptides encompassing the IGFl binding domains, and IGFl analogs comprising substituted amino acids.
  • Exemplary IGFl mimics include peptide IGF-1 mimics as described in Harb et al., The Rho-Rock- Myosin Signaling Axis Determines Cell-Cell Integrity of Self- Renewing Pluripotent Stem Cells. PLoS ONE 3(8): e3001 (2008), or in United States Patent Application Serial Number 12/659,546, by Chung et al., "Peptides having activities of insulin like growth factor- 1 and their uses.”
  • DKK1 Dickkopf-related protein
  • Recombinant DKK1 may be acquired from numerous commercial suppliers. Human derived recombinant DKK1 is preferred for the culture and differentiation of human pluripotent cells, although DKK1 derived from other mammalian species may be used as well. DKK1 mimics may be substituted for DKKlin the media. DKK1 mimics encompass any compound which recapitulates the effects of DKKlin the differentiation and maturation of RPE cells from pluripotent cells. DKK1 mimics include modified forms of DKKl, peptides encompassing the DKKl binding domains, and DKKl analogs comprising substituted amino acids.
  • Exemplary DKKl mimics include any Wnt signaling pathway inhibitor.
  • Wnt inhibitors may comprise small molecules, for example IWP-2, IWP-3, IWP-4, and XAV939 (all available from Stemgent).
  • Wnt inhibitors also include peptide inhibitors of Wnt signaling, for example as described in Gregory et al., Dkk- 1 -derived Synthetic Peptides and Lithium Chloride for the Control and Recovery of Adult Stem Cells from Bone Marrow. Journal of Biological Chemistry, 2005, Vol. 280, No. 3, pp. 2309-2323.
  • Wnt Inhibitory Factor 1 is another protein Wnt inhibitor.
  • Nicotinamide a B Vitamin
  • Nicotinamide mimics may be substituted for nicotinamide in the media. Nicotinamide mimics encompass any compound which recapitulates the effects of nicotinamide in the differentiation and maturation of RPE cells from pluripotent cells.
  • Nicotinamide mimics include modified forms of nicotinamide, and chemical analogs of nicotinamide.
  • Exemplary nicotinamide mimics include benzoic acid, 3-aminobenzoic acid, and 6-aminonicotinamide.
  • Another class of compounds that may act as nicotinamide mimics are inhibitors of poly(ADP-ribose) polymerase (PARP).
  • Exemplary PARP inhibitors include 3-aminobenzamide, Iniparib (BSI 201), Olaparib (AZD-2281), Rucaparib (AG014699, PF- 01367338), Veliparib (ABT-888), CEP 9722, MK 4827, and BMN-673.
  • BFGF1 basic fibroblast growth factor 1
  • Recombinant BFGF1 may be acquired from numerous commercial suppliers. Human derived recombinant BFGF1 is preferred for the culture and differentiation of human pluripotent cells, although BFGF1 derived from other mammalian species may be used as well.
  • BFGF 1 mimics may be substituted for BFGF 1 in the media.
  • BFGF1 mimics encompass any compound which recapitulates the effects of BFGF 1 in the differentiation and maturation of RPE cells from pluripotent cells.
  • BFGF1 mimics include modified forms of BFGF 1, peptides encompassing the BFGF1 binding domains, and BFGF1 analogs comprising substituted amino acids.
  • Exemplary BFGF1 mimics include other members of the fibroblast growth factor family, for example FGF1, FGF2, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, and FGF10.
  • the small molecule SUN13837 may also serve as a BFGF1 substitute.
  • exemplary mimics include the synthetic peptide F2A4-K- NS (as described in Lin et al., Synthetic peptide F2A4-K-NS mimics fibroblast growth factor- 2 in vitro and is angiogenic in vivo, International Journal of Molecular Medicine 17:833-839 (2006)), and trichostatin A (as described in Durcova-Hills et al., Reprogramming Primordial Germ Cells into Pluripotent Stem Cells. PLoS ONE 3(10) (2008)).
  • Activin A Another additive used to formulate the novel media of the invention is Activin A.
  • Recombinant Activin A may be acquired from numerous commercial suppliers. Human derived recombinant Activin A is preferred for the culture and differentiation of human pluripotent cells, although Activin A derived from other mammalian species may be used as well.
  • Activin A mimics may be substituted for Activin A in the media. Activin A mimics encompass any compound which recapitulates the effects of Activin A in the differentiation and maturation of RPE cells from pluripotent cells.
  • Activin A mimics include modified forms of Activin A, peptides encompassing the Activin A binding domains, and Activin A analogs comprising substituted amino acids.
  • Exemplary Activin A mimics include Activin AB, and Activin B and members of the transforming growth factor beta (TGFB) family, for example, BMP-4, BMP-7 and TGF-betal .
  • TGFB transforming growth factor
  • SU5402 Another additive used to formulate the novel media of the invention is SU5402, an FGF signaling inhibitor.
  • SU5402 mimics may be substituted for SU5402 in the media.
  • SU5402 mimics encompass any compound which recapitulates the effects of SU5402 in the differentiation and maturation of RPE cells from pluripotent cells.
  • SU5402 mimics include modified forms of SU5402, and chemical analogs of SU5402.
  • Exemplary SU5402 mimics include any FGF signaling inhibitor.
  • the protein sprouty 2 may serve as an SU5402 mimic.
  • Other SU5402 mimics include small molecule inhibitors of FGF signaling such as AZD4547 and PD 173074 (Stemgent).
  • Another additive used to formulate the novel media of the invention is vasoactive intestinal peptide (VIP), a cyclic AMP upregulator.
  • VIP vasoactive intestinal peptide
  • Recombinant VIP may be acquired from numerous commercial suppliers.
  • VIP mimics Human derived recombinant VIP is preferred for the culture and differentiation of human pluripotent cells, although VIP derived from other mammalian species may be used as well.
  • VIP mimics may be substituted for VIP in the media.
  • VIP mimics encompass any compound which recapitulates the effects of VIP in the differentiation and maturation of RPE cells from pluripotent cells.
  • VIP mimics include modified forms of VIP, peptides encompassing the VIP binding domains, and VIP analogs comprising substituted amino acids.
  • Exemplary VIP mimics include any cyclic AMP upregulator.
  • VIP mimics include, for example, small molecules such as forskolin and rolipram
  • the invention comprises six novel media, used in various stages of RPE differentiation and propagation, as described below.
  • Medium 1 comprises basal medium supplemented with biologically active concentrations of the following additives: Noggin, for example, at 1 to 100 ng/ml; IGF1 , for example, at 1 to 100 ng/ml; DKK1 , for example, at 1 to 50 ng/ml; and
  • Nicotinamide for example, at 1 to 100 mM. In Medium 1, noggin or DKK1 may be used in excess and there is no actual upper limit to the amount of that may be used. Nicotinamide is not necessary for RPE differentiation, and may be omitted, but it is included to speed up the RPE differentiation process.
  • the additives are included at the following concentrations: Noggin, at 50 ng/ml; IGF 1 , at 10 ng/ml; DKK1 , at 10 ng/ml; and
  • Medium 2 comprises basal medium supplemented with biologically active concentrations of the following additives: Noggin, for example, at 1 to 100 ng/ml; IGF1, for example, at 1 to 100 ng/ml; DKK1, for example, at 1 to 50 ng/ml; and
  • Nicotinamide for example, at 1 to 100 mM
  • BFGF for example at, at 1 to 20 ng/ml.
  • noggin or DKK1 may be used in excess and there is no actual upper limit to the amount of that may be used. Nicotinamide is again not necessary and may be omitted, but it is included to speed up the RPE differentiation process. Likewise, BFGF may also be omitted, however its inclusion in the medium improves the yield and efficiency of the process.
  • the additives are included at the following concentrations: Noggin, at 10 ng/ml; IGF1, at 10 ng/ml; DKK1, at 10 ng/ml; Nicotinamide, at 10 mM; and bFGF, 5 ng/ml.
  • MEDIUM 3 comprises basal medium supplemented with biologically active concentrations of the following additives: IGF1, for example, at 1 to 100 ng/ml;
  • DKK1 for example, at 1 to 50 ng/ml; and Activin A, for example, at 10 to 200 ng/ml.
  • DKK1 may be used in excess and there is no actual upper limit to the amount of that may be used.
  • the additives are included at the following concentrations: IGF1, at 10 ng/ml; DKK1, at 10 ng/ml; and Activin A, at 100 ng/ml.
  • MEDIUM 4 comprises basal medium supplemented with biologically active concentrations of the following additives: Activin A, for example, at 10 to 200 ng/ml; SU5402, for example at 1 to 100 ⁇ ; and VIP, for example at 0.1 to 100 ⁇ .
  • Activin A for example, at 10 to 200 ng/ml
  • SU5402 for example at 1 to 100 ⁇
  • VIP for example at 0.1 to 100 ⁇ .
  • SU5402 may be used in excess and there is no actual upper limit to the amount of that may be used.
  • VIP is not necessary and may be omitted, but its inclusion will help to speed up the RPE differentiation process.
  • the additives are included at the following concentrations: Activin A, at 100 ng/ml; SU5402, at 10 ⁇ ; and VIP, at 1 ⁇ .
  • a biologically equivalent amount means a quantity of such mimic that has the same biological effect on pluripotent cells differentiating into RPE cells as the enumerated quantity of the named additive.
  • a medium is described as containing 10 ng/ml of additive X
  • an additive X mimic may be utilized instead, the additive X mimic being used in an amount sufficient to replicate the biological effect using 10 ng of additive X.
  • Such biologically equivalent amount may be readily determined by one of skill in the art by various methods.
  • the mimic may be used in the same or nearly the same amount as the additive.
  • the mimic may be used at the concentration at which it is known to have a biological effect, as known in the art.
  • the mimic may be tested in an RPE differentiation protocol at various concentrations, and the concentration range at which the effects of the original additive are recapitulated will be the proper range for use of the mimic.
  • the invention comprises the use of subsets of the media additives described for each media composition.
  • a medium omitting one or more of the constituents of Media 1, Media 2, Media 3, Media 4, the RPE Maturation Media, or the RPE Proliferation Medium will still fall within the scope of the invention.
  • the timing of inclusion or exclusion of various media formulations or media additives in the culture media is based on the expression of molecular markers.
  • Molecular marker expression may be assayed by various standard tools known in the art, for example by quantification of messenger RNA, by quantification of gene product proteins, or functional assays (e.g.
  • Paired box protein also known as aniridia type II protein (AN2) or oculorhombin is a that in humans is encoded by the PAX6 gene
  • the Rax homeobox gene also known as Rx
  • LIM/homeobox protein (Lhx2), a protein that in humans is encoded by the LHX2 gene
  • Homeobox protein SIX3 a protein that in humans is encoded by the SIX3 gene;
  • tyrosinase enzyme is encoded by the TYR gene; Microphthalmia-associated transcription factor (MITF); Human cationic trypsinogen, encoded by the TRYP1 gene; Trypsin- 1, also known as cationic trypsinogen, in humans is encoded by the PRSS1 gene; trypsin-2 (anionic trypsinogen), in humans encoded by the PRSS2 gene; Melanocyte protein PMEL 17also known as premelanosome protein (PMEL 17) or silver locus protein homolog (SILV), in humans is encoded by the PMEL gene; ceh-10 homeo domain containing homolog (ChxlO), also known as Ceh-10 homeodomain-containing homolog; and Bestrophin- 1 , that in humans is encoded by the BEST1 gene.
  • pluripotent cells commence culture in Medium 1.
  • the initiation of culture in Medium 1 starts the protocol, and the time is referred to as "Day 0."
  • the protocol is initiated by transferring clumps of pluripotent cells, maintained as known in the art, to a new culture vessel, for example, the well of a 6-well plate, such transferred cells being plated to cover 50-75% of the culture well.
  • Medium 1 in an appropriate amount, for example 2 ml for the well of a standard six well plate, is added.
  • the medium in the culture vessel be replenished with new Medium 1.
  • Culture in Medium 1 is theorized to commence neural induction in the pluripotent cells. Cells begin to lose pluripotent morphology (high nucleus to cytoplasm ratio) and extend processes in radial orientation.
  • the medium in the culture vessel is switched to Medium 2.
  • the transition to Medium 2 may take place as early as 24 hours after the commencement of culture in Medium 1 to as late as 3 days after commencement of culture in Medium 1
  • the transition to Medium 2 is made on or about Day 2 (i.e. about 48 hours after the commencement of culture in Medium 1).
  • the transition to Medium 2 may be made within 0-24 hours of the first detectable expression or significant upregulation of any of the retinal progenitor markers Pax6, Rax, Lhx2, Six3, or the detection of any other molecular, physiological, or morphological markers of neural induction.
  • the medium in the culture vessel is switched to Medium 3.
  • the transition to Medium 3 may take place as early as Day 2 to as late as Day 6.
  • the transition to Medium 3 is made on or about Day 4.
  • the transition to Medium 3 may be made upon observing a substantial increase (e.g. 10-fold) in the expression of any of the retinal progenitor markers Pax6, Rax, Lhx2, or Six3.
  • the transition to Medium 3 may be made within 0-24 hours of first observing the expression of Mitf or ChxlO expression.
  • the transition to Medium 3 may be made upon observing the formation of rosette structures, for example, structures described in
  • the transition to Medium 3 may be made shortly after the detection of any other molecular, physiological, or morphological markers of retinal progenitor specification or early eye field differentiation. During culture in Medium 3, it is theorized that the cultured cells are undergoing RPE specification.
  • the medium in the culture vessel is switched to Medium 4.
  • the transition to Medium 4 may take place as early as Day 5 to as late as Day 8. In a preferred embodiment, the transition to Medium 4 is made on or about Day 6.
  • the transition to Medium 3 may be made upon observing a substantial decrease in the expression of Mitf, or upon the detection of expression of any RPE associated marker such as Tyrosinase (TYR), melanocyte protein PMEL 17 (SIL V), cellular retinaldehy de-binding protein (CRALBP), Trypl, Tryp2, or bestrophin.
  • the transition to Medium 3 may be made upon observing the flattening of rosette structures into sheets of immature RPE cells.
  • the differentiating cells may thereafter be maintained in Medium 4, with the medium preferentially being changed every other day.
  • the timing of the media transitions will be delayed if nicotinamide or a nicotinamide mimic is not used in Media 1 and/or Media 2. Without nicotinamide (or a mimic), the transition from Medium 1 to Medium 2 should occur on or about Day 4; the transition to Medium 3 should take place on or about Day 8, and the transition to Medium 4 should take place on or about Day 12.
  • a medium for the differentiation of pluripotent cells may comprise one or more of noggin, DKKl, IGFl, BFGF, nicotinamide, SU5402, VIP, or Activin A.
  • the invention comprises the use of a basal medium for the culture of pluripotent cells or cells differentiating into RPE cells, such basal medium optionally supplemented with a biologically active concentration of noggin and/or nicotinamide and such basal medium not containing a biologically active concentration of Activin A.
  • a basal medium for the culture of pluripotent cells or cells differentiating into RPE cells, such basal medium optionally supplemented with a biologically active concentration of noggin and/or nicotinamide and such basal medium not containing a biologically active concentration of Activin A.
  • the expression of one or more of the following molecular markers is monitored in the cultured cells: Pax6, Rax, Lhx2, Six3, Mitf, and ChxlO. After observing a substantial increase (e.g.
  • the cultured cells are thereafter cultured in a medium that does not contain either noggin or nicotinamide, and which optionally contains a biologically effective concentration of Activin A.
  • a medium that does not contain either noggin or nicotinamide, and which optionally contains a biologically effective concentration of Activin A.
  • the exclusion of noggin and/or nicotinamide or the inclusion of Activin A may be made upon observing the formation of rosette structures.
  • pluripotent cells or pluripotent cells differentiating into RPE cells are cultured in a medium which does not contain a biologically active concentration of BFGF.
  • the expression of one or more of the following molecular markers is monitored in the cultured cells: Pax6, Rax, Lhx2, and Six3.
  • the cultured cells are switched to a medium containing a biologically active concentration of BFGF.
  • the invention comprises the use of a basal medium for the culture of pluripotent cells differentiating into RPE cells, such basal medium optionally supplemented with a biologically active concentration of DKK1 and/or IGF1 and such basal medium not containing a biologically active concentration of SU5402 or VIP.
  • a basal medium for the culture of pluripotent cells differentiating into RPE cells, such basal medium optionally supplemented with a biologically active concentration of DKK1 and/or IGF1 and such basal medium not containing a biologically active concentration of SU5402 or VIP.
  • the expression of one or more of the following molecular markers is monitored in the cultured cells: Mitf, TYR, PMEL17, CRALBP, Trypl, Tryp2, or bestrophin.
  • the cultured cells are transitioned to a medium which does not contain an biologically active concentration of DKK1 or IGF1, and which optionally contains a biologically active concentration of SU5402 and/or VIP.
  • a medium which does not contain an biologically active concentration of DKK1 or IGF1, and which optionally contains a biologically active concentration of SU5402 and/or VIP.
  • the exclusion of DKK1 and/or IGF1 and/or the inclusion of SU5402 and/or VIP may be made upon observing the flattening of rosette structures into sheets of immature RPE cells.
  • X-VivoTM 10 medium (Lonza) may be utilized.
  • X-Vivo 10 may be utilized for the continued maturation of RPE cells, and the expansion and/or maintenance of differentiated RPE cells.
  • Maturation of RPE cells occurs along a continuum of increasing maturity. Lightly pigmented cells or cells with cobblestone morphology would best be described as immature RPE cells. As cells mature over time, pigmentation increases. Maturation may also be assessed by changes in gene expression over time, with the appearance of, or an increase in the expression levels of RPE markers, as known in the art, being indicative of a more mature phenotype. Maturation may also be assessed by functional assays, as known in the art. For purposes of this disclosure, maturation may be assessed by pigmentation, molecular marker expression, or functional assays.
  • RPE maturity may be assessed by the presence of genetic markers associated with functional RPE phenotype, such as MitF, Tyrosinase, Tyrpl, Tyrp2, Bestl, CRALBP, and RPE65.
  • the maturity of RPE cells may be assessed by functional assays. For example, in normal RPE cell function, RPE cells phagocytose shed rod outer segments (ROS), preventing their accumulation. Ability to phagocytose ROS is indicative of functional RPE.
  • ROS rod outer segments
  • Established assays to measure the ability of cultured putative RPE cells to phagocytose ROS are known in the art, for example as described in detail in Haruta et al., In Vitro and In Vivo Characterization of Pigment Epithelial Cells Differentiated from Primate Embryonic Stem Cells, IVOS 45: 1020- 1045 (2004) and Carr et al., Molecular
  • Additional assays for maturity include assaying for the polarized secretion of growth factors and tight junctions creating an electrical barrier, as described in Vaajasaari et al Mol. Vis. 201 1 Toward the defined and xeno-free differentiation of functional human pluripotent stem cell-derived retinal pigment epithelial cells.
  • Maturity and pigmentation is speeded up by the use of VIP in the maintenance culture medium (e.g. Media 4, or a maintenance medium to which the cells are transitioned after Media 4), for example at a concentration of 0.1 to 100 ⁇ , with a preferred concentration of 1 ⁇ . Cultures without VIP will tend to increase pigmentation and reach maturity at a lower rate.
  • the maintenance culture medium e.g. Media 4, or a maintenance medium to which the cells are transitioned after Media 4
  • Pigmentation may be promoted by changing the medium to X-Vivo 10 medium (Lonza Biosciences) after about Day 12. By about Day 30, dark pigmentation will be widespread in cultures switched to X-Vivo 10. However, changing to this medium may result in the proliferation of non-RPE type cells, reducing the percentage of RPE-type cells to about 50% of the culture vessel area.
  • RPE cells may be passaged to fresh substrate, for expansion of cultures or to enrich cultures in RPE.
  • RPE cell cultures may be enriched by mechanically removing any non-RPE cells, for example by pipette tip, followed by replating the maturing RPE cells on fresh substrate, as described below.
  • the RPE sheets can be lightly treated with protease and broken down into small pieces.
  • proteases such as dispase or collagenase may be used.
  • RPE sheets will begin to dissociate from the substrate after about 5 minutes at 37 degrees C. These sheets of cellular monolayer may then be aspirated using a 5ml pipette and gently triturated to dissociate the cells into small sections which are then placed on fresh substrate.
  • Replated sections of monolayer may be plated at any density, for example at 5%, 10%, 25%, 50%, 75% or greater coverage of the new substrate. A preferred density is in the range of 50% coverage of the new substrate.
  • Replated sections of RPE monolayers will typically maintain their differentiated state in the middle, grow to confluence from the edges, and continue maturation towards higher levels of pigmentation.
  • maturing RPE cell monolayers may be dissociated to single cells by treatment with a protease or other dissociation agent.
  • protease TrypLE is used, at the concentration supplied by Life Technologies, for example with 1 ml of the protease solution being added per well in a standard six-well plate (well diameter of 9.5 cm 2 ). Cells are exposed to the protease for 5 minutes at 37 degrees C, triturated into single cells using a PI 000 pipetman, aspirated from the culture vessel, washed in PBS buffer, centrifuged, and resuspended in medium.
  • the concentration of dissociated single RPE cells in suspensions may be quantified by any means, including the use of cell counters, hemacytometers, and other cell quantification methods known in the art. For example, a cell counter with gating diameter set between 6 and 20 ⁇ may be used.
  • the single cells may be then be replated at any desired density. For example, for expansion of the cells, they may be replated at a density of about 2.5xl0 4 cells/cm 2 and passaged when 90% confluence is reached. For maturation, cells may be seeded at a density of about lxlO 5 cells/cm 2 .
  • Replated cells may be grown on any suitable combination of substrate and medium that is known for the maintenance of RPE cultures.
  • the cells may basal medium supplemented with FBS or B27, X-Vivo 10, or any other compatible media known in the art.
  • Other exemplary media for the growth and culture of RPE cells are described in Maminishkis et al. Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. Invest Ophthalmol Vis Sci. (2006); Gamm et al. A novel serum- free method for culturing human prenatal retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2008; , Ahmado et al. Induction of differentiation by pyruvate and DMEM in the human retinal pigment epithelium cell line ARPE- 19. Invest Ophthalmol Vis Sci. 2011 ; Hu and Bok. A cell culture medium that supports the differentiation of human retinal pigment epithelium into functionally polarized monolayers. Mol Vis. 2001.
  • the replated cells may be expanded and maintained on a novel proliferation medium developed by the inventors of the present disclosure ("RPE
  • the RPE Proliferation Medium may be used for the proliferation, maintenance, or expansion of RPE cells derived from any source, for example, RPE cells derived from the protocols disclosed herein, RPE cells derived from other RPE production protocols known in the art, or native RPE cells isolated from retinas, e.g. fetal or adult eye tissues.
  • RPE cells that are cultured in medium containing fetal bovine serum tend to undergo an epithelial to mesenchymal- like transition and after several passages are unable to regain RPE morphology. It has been advantageously discovered that the use of a serum-free medium for RPE proliferation does not cause this undesired transition.
  • the novel RPE Proliferation Medium is composed of a basal medium, for example, Iscove's Modified Dulbecco's Medium (as known in the art), supplemented with one or more of the following: Insulin, for example at about 1-100 ⁇ g/ml; Holo-transferrin, for example at about 1- 10 ⁇ g/ml; Selenium, for example at about 0.001-0.3 ⁇ g/ml; Albumin, for example at about 4 ⁇ g/ml to 10 ⁇ g/ml; and Chemically Defined Lipid Concentrate (Life Technologies), for example present at a dilution of about 1 : 100 to 1 :2000.
  • Iscove's Modified Dulbecco's Medium as known in the art
  • Insulin for example at about 1-100 ⁇ g/ml
  • Holo-transferrin for example at about 1- 10 ⁇ g/ml
  • Selenium for example at about 0.001-0.3 ⁇ g/ml
  • Albumin for
  • (074) Selenium may be omitted. If selenium is already present in the basal medium, it should be accounted for when determining the amount of selenium to add to the medium. For example, selenium is already present in IMDM medium at about 0.17 ⁇ g/ml, and supplemental amounts of 0.001 to 0.1 may be added in addition to the selenium already present in this medium. Linoleic acid and cholesterol, for example at about 10 ⁇ g/ml and 4- 500 ⁇ g/ml, respectively, may be used in place of Life Technologies Chemically Defined Lipid Concentrate. It will be understood by one of skill in the art that other biologically equivalent basal medium and/or supplements may be substituted for the medium and supplements listed above.
  • RPE grown in the RPE Proliferation Medium described above tend to grow in clonal clusters and maintain a more RPE-like morphology during proliferation whereas RPE cells grown in medium containing serum take on a fibroblastic, elongated morphology and do not grow in contact with one another.
  • a basal medium e.g. IMDM
  • Insulin at about 10 ⁇ g/ml
  • Holo-transferrin at about 5.5 ⁇ g/ml
  • Selenium at about 0.18 ⁇ g/ml (0.0067 ⁇ g/ml if added to IMDM)
  • Albumin at about 4 ⁇ g/ml
  • Chemically Defined Lipid Concentrate (Life Technologies), present at a dilution of about 1 : 1000.
  • RPE Maturation Medium For efficient and optimal maturation, a novel RPE maturation medium has been developed by the inventors of the present disclosure (“RPE Maturation Medium”).
  • the RPE Maturation Medium is composed of a basal medium (e.g. Iscove's Modified Dulbecco's Medium), supplemented with B27 (for example, as described in Brewer et al., Optimized survival of hippocampal neurons in B27-supplemented neurobasalTM, a new serum- free medium combination, Neurosci. Res.
  • B27 for example at a dilution of 1 :50, and also optionally supplemented with taurine, for example at a concentration of 1-500 ⁇ g/ml, with a preferred concentration of 250 ⁇ g/ml.
  • a combination of progesterone (for example at 2uM), Vitamin A (for example at 0.5uM) and triiodothyronine (for example at ⁇ ) may be used in place of B27.
  • the novel RPE Maturation Medium is used as follows. RPE cells growing on the RPE Proliferation Medium are maintained on the same substrate until one week after confluence has been reached, at which time the RPE Maturation Medium is substituted for the RPE Proliferation Medium. Within 2-3 weeks after the medium change, the RPE cells become mature at high frequency, with maturity described and assayed as set forth above. Both the rate of maturation, and the percentage of cells becoming mature is significantly increased by the use of this medium relative to RPE cells that continue culture in the RPE Proliferation Medium.
  • ROCK inhibitors may advantageously be employed in the maintenance, expansion, and maturation of RPE cells derived from any source, for example, from pluripotent cells or native RPE cells isolated from retinas, e.g. from the eyes of patients, donors, or other sources, e.g. fetal or adult eye tissues.
  • exemplary ROCK inhibitors include Y-27632, thiazovivin, GSK429286A, and Fasudil.
  • Y-27632 may be used at a concentration ranging from 500nM to 50uM.
  • Y-27632 is a selective inhibitor of the Rho associated kinase, p 160ROCK and ROCK-II with a Ki value of 140nm.
  • Y-27632 additionally inhibits PKC, cAMP-dependent protein kinase and myosin light-chain kinase but with greatly diminished Ki values, 26, 25 and >250 ⁇ , respectively.
  • ROCK inhibitors may be used in the maturation, maintenance, expansion, or proliferation of RPE cells by including a physiologically effective amount of ROCK inhibitor as a supplement in any media known for the maintenance, proliferation, and maturation of RPE cells.
  • Y27632 may be used at a concentration ranging from about 500nM to 50uM.
  • the use of ROCK inhibitors allows replated RPE cells to retain their RPE phenotype during more passages and expansions than replated cells in media lacking ROCK inhibitors.
  • the use of the ROCK inhibitor- supplemented media for cells replated between Day 10 and about Day 20 substantially increases the survival and viability of the cells.
  • RPE cells When RPE cells are dissociated into single cells, they often lose many of their RPE characteristics when subsequently seeded and proliferated on new substrates. Culturing re-seeded single cells in medium supplemented with ROCK inhibitor improves both survival and expansion. Inclusion of ROCK inhibitor during serial passaging of RPE allows far greater expansion of cells than serial passaging without ROCK inhibitor. For example, cells cultured in XVIVOTM10, plated at a density of 2.5xl0 4 cells/cm 2 and passaged when cells reach approximately 90% confluence can be passaged greater than 14 times when ROCK inhibitor is included. If ROCK inhibitor is not included, cultures stop dividing at passage 4-7. When re- differentiation is desired, the ROCK inhibitor may be removed from the medium, for example when confluence is reached.
  • ROCK inhibitors have previously been used for survival and expansion of hESC, corneal endothelial cells, keratinocytes and other epithelial cells, for example as described in Watanabe et al., A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnoi. 25: 681 -686 (2007); and Okumura et al., The new therapeutic concept of using a Rho kinase inhibitor for the treatment of corneal endothelial dysfunction. Cornea 30(Suppl 1 ):S54-S59 (2011), but have not been previously used in the manner disclosed herein.
  • inhibitors of the ROCK-Myosin II pathway may be used in place of ROCK inhibitors.
  • Blebbistatin an inhibitor of myosin light chain II may be used at a concentration between luM and lOOuM. In a preferred embodiment, Blebbistatin is used at 1 OuM.
  • Mature RPE produced by the methods of the invention in general may be passaged and expanded for as many as 14 passages with the inclusion of ROCK inhibitor. Thereafter, the cells may be used for research purposes, for therapeutic uses, or may be cryopreserved for later use.
  • the invention comprises a method of using Media 1, Media 2, Media 3, and Media 4 in sequence to promote fast differentiation of RPE from pluripotent cells.
  • the invention comprises a specific media composition, for example Media 1, Media 2, Media 3, Media 4, the RPE Maturation Media, or the RPE Proliferation Medium.
  • the invention comprises kits which are combinations of the above-listed media.
  • the invention comprises a kit made up of Media 1, Media 2, Media 3, and Media 4.
  • the invention comprises media supplement kits made up of the media additives for a specific media, for example, the additives which are combined with a basal media to form Media 1 , Media 2, Media 3, Media 4, the RPE Maturation Media, or the RPE Proliferation Medium.
  • the media supplement kit for Media 1 would comprise DKK1, noggin, IGF1, and optionally, nicotinamide.
  • Media supplement kits could take the form of a single solution containing all the additives of a given medium, or could take the form of multiple vessels containing different additives.
  • the additives are present in such amounts that when a specified amount of the media additive kit contents is added to a specified volume of basal medium, an effective media composition is formed (e.g. Media 1, Media 2, etc.).
  • the human embryonic stem cell line H9 (WiCell Research Institute, Madison, WI, http://www.wicell.org) was maintained in Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-12 (DMEM/F12) containing 2 mM
  • GlutaMAX-I 20% knockout serum replacement, 0.1 mM Modified Eagle's Medium Non- Essential Amino Acids (MEM NEAA), 0.1 mM Beta-mercaptoethanol (Invitro-gen, Carlsbad, CA, http://www.invitrogen.com) and 4 ng/ml bFGF (Peprotech, Rocky Hill, NJ, http://www.peprotech.com) on a mitomycin C (Sigma-Aldrich, St. Louis, MO,
  • H9s for flow cytometry were grown on growth factor-reduced Matrigel (BD Biosciences, San Diego, CA, http://www. bdbiosciences.com) in mTESRl (StemCell Technologies, Vancouver, BC, Canada, http://www.stemcell.com) medium.
  • the human embryonic stem cell line UCSF4 (NIH registry no. 0044, University of California, San Francisco) was maintained on growth factor-reduced Matrigel (BD Biosciences) in mTESRl medium (StemCell Technologies).
  • the induced pluripotent stem cell line iPS(IMR90)-4 (IMR904) was maintained in
  • DMEM/F12 containing 2 mM GlutaMAX-I, 20% knock- out serum replacement, 0.1 mM MEM NEAA, 0.1 mM Beta-mercaptoethanol (Invitrogen) and 100 ng/ml recombinant zebrafish bFGF on a mitomycin C (Sigma- Aldrich)- treated mouse embryonic fibroblast feeder layer.
  • the cells were mechanically enriched by scraping away cells with non-RPE morphology. Subsequently, the remaining RPE were digested using TrypLE Express (Invitrogen) for ⁇ 5 minutes at 37°C. The cells were passed through a 30- ⁇ single-cell strainer and seeded onto Matrigel-coated tissue culture plastic, Transwell membranes (Corning Enterprises, Corning, NY, http://www.corning.com), or CC2-treated chambered slides.
  • TrypLE Express Invitrogen
  • Enriched cells were cultured in DMEM-high glucose with 1% fetal bovine serum (FBS), GlutaMAX, and sodium pyruvate (Invitrogen) for 30 days, as described in Ahmado A, Carr AJ, Vugler AA et al. Induction of differentiation by pyruvate and DMEM in the human retinal pigment epithelium cell line ARPE-19. Invest Ophthalmol Vis Sci 2011 ;52:7148 - 7159.
  • Hs27 and cultured fetal human RPE were cultured on Matrigel-coated Transwell membranes in DMEM- high glucose with 1% FBS, GlutaMAX, and sodium pyruvate (Invitrogen).
  • Me Wo cells were cultured in DMEM/F12 GlutaMAX 1 (Invitrogen) with 10% fetal bovine serum (HyClone, Logan, UT, http://www.hyclone.com).
  • RNA of RPE marker genes was isolated using primers based upon the mRNA sequences of such genes. QPCR methods were carried out with the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany,
  • cDNA was synthesized from 1 ⁇ g of RNA using the iScript cDNA Synthesis Kit (Bio- Rad, Hercules, CA, http://www.bio-rad.com). Primer pairs were designed to create a 75-200-base pair product (Beacon Design 4.0; Premier Biosoft International, Palo Alto, CA, http:// www.premierbiosoft.com). Quantitative real-time polymerase chain reaction (PCR) was carried out on a Bio-Rad MylQ Single Color Real-Time PCR Detection System using the SYBR Green method, as described in Woo TH, Patel BK, Cinco M et al.
  • PCR Quantitative real-time polymerase chain reaction
  • HMBS hydroxymethylbilane synthase
  • GPI glucose phosphate isomerase
  • FCS Express 4 Flow Research Edition (De Novo Software, Thornhill, ON, Canada, http://www.denovosoftware. com). The positive percentage was based on a background level set at 1 % positive expression in samples labeled with isotype control antibodies.
  • Rod Outer Segment Phagocytosis Rod outer segment (ROS) phagocytosis assays were performed as previously described in Lin H, Clegg DO. Integrin alphavbeta5 participates in the binding of photoreceptor rod outer segments during phagocytosis by cultured human retinal pigment epithelium. Invest Ophthalmol Vis Sci 1998;39: 1703-1712. Bovine eyes were obtained fresh from Sierra Medical Inc. (Whittier, CA, http://www.sierra- medical. com); ROSs were purified from retinal extracts and fluorescently labeled using the FluoReporter FITC Protein Labeling Kit (Invitrogen).
  • the cells were seeded in quadruplicate on gelatin-coated wells in a 96-well plate at a concentration of 25,000 -50,000 cells per well and allowed to grow to confluence for 4 weeks.
  • the cells were then challenged with 1 X 10 6 fluorescein isothiocyanate- labeled ROSs per well with or without 50 ⁇ g/ml anti-avB5 (ab24694; Abeam, Cambridge, U.K., http://www.abcam.com) or 50 ⁇ g/ml IgGl control (ab9404; Abeam) for 5 hours at 37°C in 5% C02.
  • the wells were then vigorously washed five times with warm PBS to remove unbound ROSs.
  • ROS internalization To determine the level of ROS internalization, an equal volume of 0.4% trypan blue was added to the PBS for 10 minutes to quench extracellular fluorescence. Trypan blue was aspirated, and 40 ⁇ of PBS was added to the well to prevent the cells from drying out. The internalized ROSs were then documented in fluorescence photomicrographs. Fluorescence intensity was quantified by pixel densitometry using ImageJ software (National Institutes of Health, Bethesda, MD) for photomicrograph analysis. Photomicrographs from three wells for each condition were averaged within each assay. Separate experiments were normalized to the positive control ARPE-19 cell line, which was assayed in each experiment.
  • Nicotinamide Speeds Up Early Eye Field Differentiation Because nicotinamide had previously been shown to increase differentiation of RPE from pluripotent stem cells in Idelson M, Alper R, Obolensky A et al. Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. Cell Stem Cell 2009;5 :396-408, it was tested whether nicotinamide would influence differentiation at early stages of eye field development. In this first segment of differentiation, cell clumps are mechanically dissected from pluripotent stem cell colonies and seeded on Matrigel in the presence of IGF 1, Noggin, and DKK1. On day 2, bFGF is added.
  • nicotinamide significantly decreased expression of the pluripotency genes Oct4 and Nanog on day 4 compared with controls.
  • Expression of early neural/early eye field markers Lhx2 and Rax increased in the presence of nicotinamide on day 4 compared with controls; however, the increase in Rax was not significant.
  • Pax6(-5a) expression was similar between nicotinamide and control conditions.
  • Cells in the presence of nicotinamide rapidly adopted a radial/rosette morphology compared with control cells, which still contained a large percentage of cells with undifferentiated morphology. Control cells expanded more rapidly than cells in nicotinamide.
  • Nicotinamide can have many effects on cultured cells, including inhibition of poly(ADP-ribose) polymerase (PARP), which can protect cells from oxidative stress.
  • PARP poly(ADP-ribose) polymerase
  • 3-Aminobenzamide reduced levels of Oct4 and Nanog compared with controls on day 4, but not as much as nicotinamide.
  • 3-aminobenz- amide significantly increased levels of Lhx2 and Rax compared with controls on day 4, but not as much as nicotinamide.
  • 3- aminobenzamide was able to partially recapitulate the effects of nicotinamide.
  • Activin A, SU5402, and VIP Direct Early Eye Field Cells to an RPE Fate. Following the acquisition of early eye field markers by day 4 (Fig. IB), it was sought to direct the cell to RPE instead of neural retina. With this in mind, the addition of nicotinamide (added days 0 - 4) was phased out, Noggin (added days 0 - 4), bFGF (added days 2-4), IGF 1 (added days 0- 6), and Dkkl (added days 0-6) and tested the effect of Activin A, SU5402, and VIP on RPE specification.
  • Quantitative polymerase chain reaction (qPCR) analysis showed that compared with cells differentiated in B27/N2 containing basal medium only (no factor differentiation), cells that had been exposed to RPE differentiation factors (nicotinamide, IGF1, DKK1, Noggin, bFGF, Activin A, SU5402, and VIP) had significantly increased levels of the RPE marker genes Mitf, Tyrosinase, Tyrp2, PEDF, BEST1, and Pmell7. Additional immunocytochemistry revealed Mitf expression exclusively in pigmenting sheets of cells, whereas Lhx2 and ZOl could be found in both pigmenting sheets and non-RPE cells.
  • RPE differentiation factors nicotinamide, IGF1, DKK1, Noggin, bFGF, Activin A, SU5402, and VIP
  • the differentiation protocol was tested on two additional pluripotent stem cell lines: the embryonic stem cell line UCSF4 and the induced pluripotent stem cell line IMR904.
  • Oct4 and Nanog expression increased slightly between days 4 and 6, during which time Activin A was added to the protocol.
  • Early neural and eye field markers (Lhx2, Pax6(-5a), Pax6(+5a), and Rax) were expressed as early as day 2, with expression increasing throughout the 14-day time period with the exception of Rax.
  • Rax expression was transient, increasing from days 2- 6 and then rapidly decreasing between days 6 and 8.
  • IGF1 and DKK1 were removed from the protocol, whereas SU5402 and VIP were added, which could account for the decrease in Rax expression.
  • RPE marker genes were expressed slightly later in two phases, between days 4 and 6 (Mitf, PEDF, and BESTl) and between days 6 and 8 (Pmell7, Tyrosinase, and Tyrp2). Interestingly, Otx2 mRNA and protein were expressed at relatively consistent levels throughout differentiation.
  • hESC-RPE To determine whether these hESC-RPE were functional, their ability to carry out phagocytosis of fluorescently labeled ROSs was tested. Compared with the negative control Hs27 cells, hESC-RPE internalized significantly more ROSs. This internalization was blocked by an antibody against integrin avB5, showing that both hESC-RPE and fRPE use the same receptor for ROS phagocytosis. hESC-RPE ROS phagocytosis was even greater than that of fRPE, although both RPE lines internalized significantly more ROSs than Hs27 cells.
  • Nicotinamide has previously been used to differentiate pluripotent stem cells into RPE. It was shown that nicotinamide had an antiapoptotic effect following 2 weeks of differentiation, in line with other studies showing neural protection by nicotinamide. Based on previous research, it was suggested that this action could be through inhibition of poly(ADP-ribose) polymerase- 1 (PARPl), which was found to regulate cell death upon hESC neural induction. In these experiments, the addition of nicotinamide to retinal inducing factors IGFl, DKKl, Noggin, and bFGF decreased expression of pluripotency genes while concomitantly increasing neural/early eye field genes by day 4.
  • PARPl poly(ADP-ribose) polymerase- 1
  • Nicotinamide was found to be a useful tool to speed up initial neural differentiation and could potentially be applied to other neural differentiation protocols.
  • ROCK inhibition has been used successfully to maintain survival of hESCs dissociated into single cells as well as to enhance proliferation of certain epithelial cell types.
  • the mechanism of ROCK inhibition has been worked out in hESCs, where ROCK mediates E-cadherin cell adhesion sensing.
  • Primary RPE cultures when dissociated into single cells over several passages, lose their ability to redifferentiate into mature RPE and become fibroblastic in morphology. This may be a wound response for an epithelium that does not normally exist as single cells and may be similar to the effect seen following single-cell dissociation on day 14 of differentiation.
  • ROCK inhibitor can generate homogenous populations that express RPE marker genes at similar levels to cultured fetal human RPE, express proper RPE proteins, are polarized, and display integrin avB5 -dependent phagocytosis of rod outer segments.

Abstract

La présente invention concerne le domaine de la culture cellulaire, spécifiquement la dérivation de cellules épithéliales pigmentées de la rétine à partir de cellules multipotentes. L'invention comprend l'utilisation de divers suppléments de milieu de culture cellulaire, de formulations de milieu et de procédés d'utilisation desdits suppléments et formulations de milieu, afin d'effectuer la rapide différentiation de cellules multipotentes en cellules épithéliales pigmentées de la rétine avec des rendements très élevés. L'invention comprend en outre des formulations de milieux de culture cellulaire pour la maintenance, la propagation et la maturation efficaces de cellules épithéliales pigmentées de la rétine cultivées.
EP13799830.8A 2012-06-05 2013-06-05 Procédés et compositions pour la production rapide de cellules épithéliales pigmentées de la rétine à partir de cellules multipotentes Active EP2882846B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261655977P 2012-06-05 2012-06-05
PCT/US2013/044325 WO2013184809A1 (fr) 2012-06-05 2013-06-05 Procédés et compositions pour la production rapide de cellules épithéliales pigmentées de la rétine à partir de cellules multipotentes

Publications (3)

Publication Number Publication Date
EP2882846A1 true EP2882846A1 (fr) 2015-06-17
EP2882846A4 EP2882846A4 (fr) 2016-07-06
EP2882846B1 EP2882846B1 (fr) 2018-09-05

Family

ID=49712594

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13799830.8A Active EP2882846B1 (fr) 2012-06-05 2013-06-05 Procédés et compositions pour la production rapide de cellules épithéliales pigmentées de la rétine à partir de cellules multipotentes

Country Status (4)

Country Link
US (1) US9458428B2 (fr)
EP (1) EP2882846B1 (fr)
ES (1) ES2688019T3 (fr)
WO (1) WO2013184809A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP2929782A1 (fr) 2004-01-23 2015-10-14 Ocata Therapeutics, Inc. Modalités améliorées pour le traitement de maladies dégénératives de la rétine
CA3006687C (fr) 2007-10-12 2024-01-09 Astellas Institute For Regenerative Medicine Procedes ameliores pour la production de cellules rpe et de compositions de cellules rpe
WO2011063005A2 (fr) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Procédés de génération de cellules humaines de l'épithélium pigmentaire rétinien (rpe) et préparations pharmaceutiques de celles-ci
EP3323884A1 (fr) 2013-02-01 2018-05-23 The United States Of America as Represented by the Secretary, Department of Health an Human Service Procédé de génération de cellules de l'épithélium pigmentaire rétinien (epr) à partir de cellules souches pluripotentes induites (ipscs)
PT2970903T (pt) * 2013-03-15 2024-02-26 Astellas Inst For Regenerative Medicine Fotorrecetores e progenitores de fotorrecetores produzidos a partir de células estaminais pluripotentes
AU2014246962A1 (en) 2013-04-03 2015-11-19 Tampereen Yliopisto Methods and media for differentiating eye cells
EP3070162B1 (fr) * 2013-11-11 2019-09-18 Sumitomo Chemical Company, Limited Procédé de production de cellules épithéliales de pigment rétinien
JP2017504311A (ja) 2013-12-11 2017-02-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 網膜色素上皮細胞を生成する方法
WO2015175504A1 (fr) * 2014-05-12 2015-11-19 The Johns Hopkins University Différenciation de cellules souches pluripotentes humaines en cellules d'épithélium pigmentaire rétinien faisant appel à des inhibiteurs de hif-1
EP3240890B1 (fr) 2014-12-30 2021-06-16 Cell Cure Neurosciences Ltd. Évaluation de populations de cellules épithéliales pigmentaires rétiniennes
EP3240892B9 (fr) 2014-12-30 2020-07-22 Cell Cure Neurosciences Ltd. Populations de cellules de l'epr et leurs procédés de production
JP6964068B2 (ja) 2015-04-03 2021-11-10 プロパジェニクス インコーポレイテッド 上皮細胞のエキソビボ増殖
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
EP3862425A1 (fr) 2015-07-29 2021-08-11 Hadasit Medical Research Services and Development Ltd. Production à grande échelle de cellules épithéliales pigmentaires rétiniennes
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CA2993910A1 (fr) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation de photorecepteurs pour le traitement de maladies retiniennes
DK3331994T3 (da) 2015-08-05 2022-11-21 Cell Cure Neurosciences Ltd Fremstilling af retinale pigmentepitelceller
CA2997763A1 (fr) * 2015-09-08 2017-03-16 Cellular Dynamics International, Inc. Purification basee sur le tri cellulaire magnetique macs d'epithelium pigmentaire retinien derive de cellules souches
AU2016320991C1 (en) * 2015-09-08 2023-04-06 Healios K.K. Method for producing retinal pigment epithelial cells
EP3892717A1 (fr) 2015-09-11 2021-10-13 Propagenix Inc. Prolifération de cellules épithéliales ex vivo
CA3002156A1 (fr) 2015-10-20 2017-04-27 FUJIFILM Cellular Dynamics, Inc. Production de cellules precurseurs hematopoietiques a lignees multiples par programmation genetique
WO2017072763A1 (fr) 2015-10-26 2017-05-04 Cell Cure Neurosciences Ltd. Préparation de cellules de l'épithélium pigmentaire rétinien
CN106754718A (zh) * 2016-12-19 2017-05-31 胡其锐 一种人胚胎干细胞快速定向分化至视网膜色素上皮细胞的方法
JP7007686B2 (ja) 2017-03-08 2022-01-25 大日本住友製薬株式会社 網膜色素上皮細胞の製造方法
WO2019078781A1 (fr) * 2017-10-17 2019-04-25 National University Of Singapore Systèmes et méthodes pour la production de progéniteurs de photorécepteurs
CN109423480B (zh) * 2017-12-21 2022-04-12 中山大学中山眼科中心 一种人多能干细胞分化为视网膜组织的简易高效可机械化的诱导方法
CN108192856B (zh) * 2017-12-27 2020-05-12 山东大学 一种高效分离和培养人原代黑色素细胞的方法
DK3810758T3 (da) * 2018-06-20 2023-10-16 Biolamina Ab Metoder og sammensætninger til fremstilling af retina pigment epitelceller
CA3124357A1 (fr) * 2018-12-21 2020-06-25 The Regents Of The University Of California Procede de production de neurones enteriques et leurs utilisations
AU2020336302A1 (en) 2019-08-23 2022-03-03 Sana Biotechnology, Inc. CD24 expressing cells and uses thereof
WO2021092047A1 (fr) * 2019-11-04 2021-05-14 Rubius Therapeutics, Inc. Procédés de génération de cellules érythroïdes énucléées à l'aide de taurine ou d'hypotaurine
IL300516A (en) 2020-08-13 2023-04-01 Sana Biotechnology Inc Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
CN114438030A (zh) * 2020-11-05 2022-05-06 中国科学院动物研究所 将胚胎干细胞诱导为视网膜色素上皮细胞的培养基及应用
IL308097A (en) 2021-05-27 2023-12-01 Sana Biotechnology Inc Hypoimmunogenic cells that include transgenic HLA-E or HLA-G
AU2022309875A1 (en) 2021-07-14 2024-01-25 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023019226A1 (fr) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Cellules génétiquement modifiées pour une thérapie cellulaire allogénique
CA3227613A1 (fr) 2021-08-11 2023-02-16 William Dowdle Systemes inductibles pour modifier l'expression genique dans des cellules hypoimmunogenes
CN115873797A (zh) * 2021-09-29 2023-03-31 北京干细胞与再生医学研究院 一种视网膜色素上皮细胞的扩增培养基及培养方法
WO2023183313A1 (fr) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Cellules d'ingénierie avec un transgène dans un locus b2m ou ciita et compositions et procédés associés

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU702871B2 (en) 1993-08-23 1999-03-11 Nexell Therapeutics Inc. (In vitro) growth of neutrophil and megakaryocyte precursors in serum-free media
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
GB2460552B (en) * 2008-06-05 2011-09-07 Iti Scotland Ltd Stem cell culture media and methods
US20110243898A1 (en) * 2008-12-10 2011-10-06 The University Of Louisville Research Foundation, Inc. Somatic cell-derived pluripotent cells and methods of use therefor
AU2010315712B2 (en) * 2009-10-19 2014-04-17 FUJIFILM Cellular Dynamics, Inc. Cardiomyocyte production
EP2383333B1 (fr) * 2010-04-28 2015-05-27 Technische Universität Dresden Procédé de production de cellules souches rétiniennes polarisées à partir de cellules souches pluripotentes et leur différentiation en cellules épithéliales pigmentées de la rétine
PL2577318T3 (pl) 2010-05-25 2019-12-31 Memorial Sloan-Kettering Cancer Center Sposób różnicowania ludzkich embrionalnych komórek macierzystych do nocyceptorów i ich zastosowania
US20120101024A1 (en) * 2010-10-26 2012-04-26 Regenerative Research Foundation Methods and Compositions for Differentiating Embryonic Stem Cells

Also Published As

Publication number Publication date
EP2882846A4 (fr) 2016-07-06
WO2013184809A1 (fr) 2013-12-12
ES2688019T3 (es) 2018-10-30
EP2882846B1 (fr) 2018-09-05
US20150175964A1 (en) 2015-06-25
US9458428B2 (en) 2016-10-04

Similar Documents

Publication Publication Date Title
US9458428B2 (en) Methods and compositions for the rapid production of retinal pigmented epithelial cells from pluripotent cells
Buchholz et al. Rapid and efficient directed differentiation of human pluripotent stem cells into retinal pigmented epithelium
US20200370007A1 (en) Methods of generating human inner ear sensory epithelia and sensory neurons
KR102487142B1 (ko) 만능 세포를 분화시키는 방법
ES2747803T3 (es) Método de diferenciación a nociceptores de células madre embrionarias humanas y sus usos
JP5631210B2 (ja) 多能性幹細胞からのニューロン細胞の生成
EP3683306A1 (fr) Procédé de production de tissus rétiniens
JP2018531027A6 (ja) 多能性幹細胞からのヒト皮膚オルガノイドの誘導
JP2018531027A (ja) 多能性幹細胞からのヒト皮膚オルガノイドの誘導
JP2018531031A6 (ja) ヒト内耳感覚上皮および感覚ニューロンを生成する方法
US20130122589A1 (en) Targeted differentiation of stem cells
WO2010140698A1 (fr) Procédé pour induire une différenciation des cellules de la crête neurale à partir de cellules souches pluripotentes
EP3683304A1 (fr) Procédé d'amplification de photorécepteurs de cônes ou photorécepteurs de bâtonnets à l'aide d'un transmetteur de signal de dorsalisation ou un transmetteur de signal de ventralisation
Zhu et al. Directed differentiation of human embryonic stem cells to neural crest stem cells, functional peripheral neurons, and corneal keratocytes
WO2019023793A1 (fr) Génération de cellules progénitrices de neurones oligodendrogéniques
US20210024888A1 (en) Generation of oligodendrogenic neural progenitor cells
WO2022110494A1 (fr) Procédé de reprogrammation d'une cellule
JP2008532509A (ja) 方向づけられた神経分化
JP2022528737A (ja) Ａｂｃｇ２陽性角膜輪部幹細胞を得る又は維持する方法
Kaur et al. Neural stem cell assays
WO2024003349A1 (fr) Amélioration de la différenciation neuronale de cellules progénitrices neurales du mésencéphale ventral
WO2024068934A1 (fr) Substrat et protocole de culture cellulaire de laminine
CA3192264A1 (fr) Procede de differenciation de cellules de type cellules endotheliales corneennes a partir de cellules souches pluripotentes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150410

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0793 20100101ALI20160208BHEP

Ipc: C12N 5/079 20100101ALI20160208BHEP

Ipc: C12N 5/02 20060101AFI20160208BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160603

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/079 20100101ALI20160530BHEP

Ipc: C12N 5/02 20060101AFI20160530BHEP

Ipc: C12N 5/0793 20100101ALI20160530BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170222

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180327

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER AND PEDRAZZINI AG, CH

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1037828

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013043250

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2688019

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20181030

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181206

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1037828

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190105

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190105

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013043250

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20190524

Year of fee payment: 7

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20190529

Year of fee payment: 7

Ref country code: IE

Payment date: 20190610

Year of fee payment: 7

26N No opposition filed

Effective date: 20190606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20190409

Year of fee payment: 7

Ref country code: MT

Payment date: 20190619

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200605

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200605

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230417

Year of fee payment: 11

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230525

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230510

Year of fee payment: 11

Ref country code: FR

Payment date: 20230411

Year of fee payment: 11

Ref country code: DE

Payment date: 20230412

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230413

Year of fee payment: 11

Ref country code: ES

Payment date: 20230707

Year of fee payment: 11

Ref country code: CH

Payment date: 20230702

Year of fee payment: 11